Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cura Therapeutics LLC maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. This same count of 2 applies to both the distinct examiners and the distinct art units involved in the prosecution. This distribution shows a degree of diversification in the company's efforts, as the applications are being reviewed by different technical groups and individuals. The focus on Biotechnology & Pharmaceuticals indicates that the company is likely protecting specific biological mechanisms or pharmaceutical compounds.
The busiest examiner for this portfolio is HUTTER, GILLIAN A, who is responsible for 1 busiest examiner pending office action. Given the total volume of 2 pending office actions, this examiner handles a portion of the company's current active workload. The presence of multiple distinct examiners and art units suggests that Cura Therapeutics LLC is pursuing different technical paths or inventions within the Biotechnology & Pharmaceuticals sector. This variety provides the company with different points of entry and review within the patent office, which can be a strategic advantage in complex biotechnology fields.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625698 | PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | COLEMAN, BRENDA LIBBY | 89d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625698 | PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | COLEMAN, BRENDA LIBBY | 89d overdue |
| 17989981 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | HUTTER, GILLIAN A | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17989981 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | HUTTER, GILLIAN A | 1625 | §112 | Non-Final OA | 10d overdue | Pending | Nov 18, 2022 |
| 17625698 | PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | COLEMAN, BRENDA LIBBY | 1624 | §102§112Other | Non-Final OA | 89d overdue | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial